Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM201 in Advanced TP53wt Tumors
NCT02143635Phase 1Completed
- Sponsor
- Novartis
- Start
- Jul 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of siremadlin in solid tumor (advanced stage), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 1 more (4 arms), sponsored by Novartis. Primary endpoint: Incidence of dose limiting toxicities up to 28 days. Started Jul 2014; status: completed.
02
Drugs
siremadlin
03
Conditions
solid tumor (advanced stage)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02143635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02143635.